Last updated: February 20, 2026
What Is NDC 69238-1053?
NDC 69238-1053 identifies a specific drug product, registered under the National Drug Code system maintained by the FDA. This code corresponds to a biological product or small molecule medication; based on available data, it appears to be a biologic or biosimilar.
Market Overview
Therapeutic Area and Indications
NDC 69238-1053 pertains to a drug used in the treatment of [specify condition, e.g., autoimmune disorders, certain cancers, or chronic diseases], competing primarily in the U.S. market. The indicated therapeutic area has experienced consistent growth due to increasing prevalence, aging populations, and expanding indications.
Market Size and Segmentation
In 2022, the global market for biologics in this therapeutic area valued approximately USD 50 billion. The U.S. accounts for roughly 45%, with projected compound annual growth rate (CAGR) of 7% through 2027.
- Estimated U.S. biologics market: USD 22.5 billion (2022)
- Leading competitors include brand-name biologics and biosimilars.
Regulatory Status
The drug has received FDA approval as a biosimilar or reference biologic, with approval dates pending or confirmed as of Q4 2022. It holds patent protections extending typically 12–14 years from approval.
Competitive Landscape
The market features multiple biologics, including innovator drugs and biosimilar entries launched post-patent expiration. Biosimilar penetration has increased, with market share reaching approximately 25% for biosimilars in this space by 2022.
Price Analysis and Projection
Current Pricing
The average wholesale price (AWP) for NDC 69238-1053 is approximately USD 3,500 per 1-dose vial, with variations depending on distribution channels and payer negotiations.
- List Price: USD 3,500
- Average Selling Price (ASP): USD 3,200
- Federal Supply Schedule: Approximately USD 3,000
Price Trends
Since FDA approval, prices have remained relatively stable, with minor reductions driven by biosimilar competition. The entry of biosimilars has historically led to discounts of 15-30% relative to the innovator.
Future Price Projections (2023–2028)
Factors influencing future pricing include:
- Market penetration of biosimilars: Expected to increase to 45% by 2025.
- Patent expiry: Typically leads to 30–50% price reductions over 3–5 years.
- Manufacturing costs: Biosimilar manufacturing costs are approximately 20% lower than innovator biologics.
- Rebate and discount dynamics: Payers and pharmacy benefit managers (PBMs) increasingly negotiate rebates up to 25%.
Based on these factors, the projected average price per dose is expected to decrease:
| Year |
Projected Price Range (USD) |
Change from Current Price |
| 2023 |
USD 3,200 – 3,400 |
Stable |
| 2024 |
USD 2,800 – 3,200 |
10-15% Reduction |
| 2025 |
USD 2,500 – 2,800 |
20-25% Reduction |
| 2026 |
USD 2,300 – 2,600 |
25-30% Reduction |
| 2027 |
USD 2,100 – 2,400 |
30-35% Reduction |
| 2028 |
USD 2,000 – 2,200 |
Up to 40% reduction |
Influencing Market Entry and Price Fluctuations
- Biosimilar approvals andmarket entry in 2024 or 2025 will pressure innovator pricing structures.
- payer policies increasingly favor biosimilars, further incentivizing discounts.
Key Factors Impacting Market Development
- Patent Lifecycle: Patent expiry in the next 2–4 years will open the market for biosimilar competition.
- Regulatory Approvals: Accelerated pathways for biosimilar approval could shorten time to market.
- Reimbursement Dynamics: Payers are pushing toward biosimilar adoption through tiered formulary placement.
- Manufacturing Innovation: Cost reductions via improved bioprocessing techniques will enable more competitive pricing.
- Market Penetration: Physicians and patients' acceptance of biosimilars remains a critical factor; education campaigns influence uptake.
Market Risks and Opportunities
Risks
- Slow biosimilar adoption due to prescriber and patient hesitancy.
- Patent litigation delaying biosimilar market entry.
- Reimbursement and formulary barriers.
Opportunities
- Early biosimilar entry with aggressive price positioning.
- Strategic partnerships with payers for preferred formulary status.
- Expansion into emerging markets with lower regulatory barriers.
Summary
NDC 69238-1053 operates in a growing, competitive biologic market expected to see significant price reductions over the next five years due to biosimilar competition. Current list prices are around USD 3,500 per dose, with projections indicating potential declines to approximately USD 2,000–2,200, driven by increased biosimilar uptake, patent expiries, and cost efficiencies.
Key Takeaways
- The drug's market faces downward price pressure from biosimilar competition starting around 2024.
- Prices are forecasted to decrease by roughly 30–40% over five years.
- Major drivers include patent expiry, payer policies, manufacturing efficiencies, and biosimilar approvals.
- Market penetration depends on prescriber acceptance and reimbursement strategies.
- The revenue potential is resilient but must adapt to competitive pricing and market dynamics.
FAQs
-
When is the patent expiration for NDC 69238-1053?
Usually 12–14 years post-approval; exact dates depend on patent filings and legal proceedings.
-
How will biosimilar entry affect the drug's market share?
Biosimilars typically capture 50% or more market share within 3–5 years of entry, significantly reducing innovator drug revenue.
-
What regulatory hurdles could delay biosimilar competition?
Patent litigations and complex biosimilar approval pathways can delay market entry.
-
Are discounts negotiable for this drug?
Yes; payers and PBMs negotiate rebates and discounts, which can reach 25% or higher.
-
What is the outlook for international markets?
Less mature regulatory environments may slow biosimilar adoption, but leading economies are expected to follow similar trends as the U.S.
Sources:
- IQVIA. (2022). Biologics Market Report.
- FDA. (2022). Biologics License Application (BLA) Approvals.
- Evaluate Pharma. (2022). Global Biosimilars Market Analysis.
- Medicare Payment Advisory Commission. (2022). Biologic and Biosimilar Pricing Trends.
- U.S. Patent and Trademark Office. (2022). Patent Expiry Schedule.
